Complete cure, at least 3 months after the end of treatment · People with American cutaneous and mucocutaneous leishmaniasis
Meglumine antimoniate (IMMA) (20 mg/kg/d for 20 days) showed no clear difference in complete cure, at least 3 months after the end of treatment compared with placebo (3 tablets/4 times a day (moderate certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · People with American cutaneous and mucocutaneous leishmaniasis
Meglumine antimoniate (IMMA) (20 mg/kg/d for 20 days) probably leads to higher adverse effects (number of participants who had at least one adverse… compared with placebo (3 tablets/4 times a day (moderate certainty).
1 finding from 1 review
Recurrence · People with American cutaneous and mucocutaneous leishmaniasis
Meglumine antimoniate (IMMA) (20 mg/kg/d for 20 days) showed no clear difference in recurrence compared with placebo (3 tablets/4 times a day (low certainty).
1 finding from 1 review
Use of physical restraints · older people in all long‐term care settings
1 finding from 1 review
Serious adverse events related to the use of physical restraints ‐ not measured · older people in all long‐term care settings
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Duration of physical restraint use ‐ not measured · older people in all long‐term care settings
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Falls · older people in all long‐term care settings
1 finding from 1 review
Fall‐related injuries ‐ not measured · older people in all long‐term care settings
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Residents with at least one psychotropic medication ‐ not measured · older people in all long‐term care settings
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Complete cure, at least 3 months after the end of treatment · People with American cutaneous leishmaniasis
Topical imiquimod 5% (3 times/week) + meglumine antimoniate (IVMA)… showed no clear difference in complete cure, at least 3 months after the end of treatment compared with placebo + IVMA (moderate certainty).
1 finding from 1 review
Adverse effects (number of participants who had the event) · People with American cutaneous leishmaniasis
1 finding from 1 review
Recurrence ‐ not measured · People with American cutaneous leishmaniasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Complete cure, at least 3 months after the end of treatment · People with American cutaneous leishmaniasis
Pentoxifylline (oral 400 mg thrice daily) plus meglumine antimoniate… showed no clear difference in complete cure, at least 3 months after the end of treatment compared with IMMA plus placebo (moderate certainty).
1 finding from 1 review
Adverse effects · People with American cutaneous leishmaniasis
1 finding from 1 review
Recurrence ‐ not measured · People with American cutaneous leishmaniasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk for at least one adverse event per patient · patients with chronic kidney disease (CKD) pruritus
It is very uncertain whether summary of findings table ‐ Gabapentin changes risk for at least one adverse event per patient compared with pregabalin (very low certainty).
1 finding from 1 review
Risk for at least one adverse drug reaction (ADR) per participant · patients with chronic kidney disease (CKD) pruritus
Summary of findings table ‐ Kappa‐opioid agonists may leads to higher risk for at least one adverse drug reaction (ADR) per patient compared with placebo (low certainty).
1 finding from 1 review
Risk for at least one adverse event per patient · patients with chronic kidney disease (CKD) pruritus
It is very uncertain whether summary of findings table ‐ Ondansetron changes risk for at least one adverse event per patient compared with placebo (very low certainty).
1 finding from 1 review
Risk for at least one adverse event per participant ‐ not measured · patients with chronic kidney disease (CKD) pruritus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk for at least one adverse event per patient · patients with chronic kidney disease (CKD) pruritus
1 finding from 1 review